0310 Aveo
BioCentury & Getty Images

Regulation

Tivozanib, at last, is Aveo’s first approved drug in the U.S. 

More than $200M and a new Phase III trial later, tivozanib reaches the market for kidney cancer

More than $200M and a new Phase III trial later, tivozanib reaches the market for kidney cancer. 

Mar 11, 2021 | 3:04 AM GMT

After nine years and more than $200 million raised since Aveo first submitted tivozanib to FDA in 2012, the drug has been approved by the agency for renal cell carcinoma, giving the company its first approved drug in the U.S.

Shares of Aveo Pharmaceuticals

Read the full 964 word article

How to gain access

Continue reading with a
two-week free trial.